{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:54:37Z","timestamp":1785333277890,"version":"3.55.0"},"reference-count":20,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2021,10,3]]},"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>A 21-year-old man developed progressive and bilateral lower limb numbness, gait impairment and urinary incontinence over 10 days. He had received intrathecal methotrexate 20 days previously for acute lymphoblastic B-cell leukaemia, following 7\u2009months of systemic chemotherapy. MR scan of the spinal cord showed bilateral symmetric and extensive T2\/fluid attenuated inversion recovery (FLAIR) increased signal involving the dorsal columns in the thoracic cord. His serum folate concentration was at the lower end of the normal range. We stopped the intrathecal chemotherapy and gave folate; after a few days, he progressively improved. Myelopathy is an important adverse effect of intrathecal methotrexate, which may cause clinical and imaging features resembling subacute combined degeneration of the spinal cord. CNS infiltration must be excluded, intrathecal chemotherapy stopped and deficiency of folate or vitamin B12 treated as appropriate.<\/jats:p>","DOI":"10.1136\/practneurol-2021-003154","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T13:25:59Z","timestamp":1635513959000},"page":"141-144","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Myelopathy associated with intrathecal methotrexate"],"prefix":"10.1136","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7706-9610","authenticated-orcid":false,"given":"Pedro Gustavo Barros","family":"Rodrigues","sequence":"first","affiliation":[{"name":"Division of Neurology, Department of Clinical Medicine, Universidade Federal do Cear\u00e1, Fortaleza, Cear\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talles Tavares de","family":"Lima","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Hospital Universit\u00e1rio Lauro Wanderley, Jo\u00e3o Pessoa, Para\u00edba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Barroso","family":"Duarte","sequence":"additional","affiliation":[{"name":"Department of Surgery, Universidade Federal do Cear\u00e1, Fortaleza, Cear\u00e1, Brazil"},{"name":"Division of Cell Processing, Centro de Hematologia e Hemoterapia do Ceara, Fortaleza, Cear\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Ribeiro","family":"N\u00f3brega","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Clinical Medicine, Universidade Federal do Cear\u00e1, Fortaleza, Cear\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"2025090409162505000_22.2.141.1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11060-015-1727-z","article-title":"Myelopathy following intrathecal chemotherapy in adults: a single institution experience","volume":"122","author":"Cachia","year":"2015","journal-title":"J Neurooncol"},{"key":"2025090409162505000_22.2.141.2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1179\/2045772312Y.0000000081","article-title":"Dorsal column myelopathy following intrathecal chemotherapy for acute lymphoblastic leukemia","volume":"37","author":"Joseph","year":"2014","journal-title":"J Spinal Cord Med"},{"key":"2025090409162505000_22.2.141.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0645-y"},{"key":"2025090409162505000_22.2.141.4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ajh.24611","article-title":"Dorsal column myelopathy after intrathecal chemotherapy for leukemia","volume":"92","author":"Pinnix","year":"2017","journal-title":"Am J Hematol"},{"key":"2025090409162505000_22.2.141.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2006.09.005"},{"key":"2025090409162505000_22.2.141.6","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jocn.2012.06.018","article-title":"Methotrexate-Induced myelopathy mimicking subacute combined degeneration of the spinal cord","volume":"20","author":"Gosavi","year":"2013","journal-title":"J Clin Neurosci"},{"key":"2025090409162505000_22.2.141.7","doi-asserted-by":"publisher","DOI":"10.1177\/0883073814527157"},{"key":"2025090409162505000_22.2.141.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.4728"},{"key":"2025090409162505000_22.2.141.9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23502"},{"key":"2025090409162505000_22.2.141.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.pmrj.2013.08.491","article-title":"Irreversible spinal cord injury following intrathecal chemotherapy: a case report","volume":"5","author":"Ng","year":"2013","journal-title":"PM&R"},{"key":"2025090409162505000_22.2.141.11","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1200\/JCO.1997.15.8.2800","article-title":"Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer","volume":"15","author":"Quinn","year":"1997","journal-title":"J Clin Oncol"},{"key":"2025090409162505000_22.2.141.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.056"},{"key":"2025090409162505000_22.2.141.13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/14737175.6.5.635","article-title":"Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma","volume":"6","author":"Green","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"2025090409162505000_22.2.141.14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cell.2018.10.049","article-title":"Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment","volume":"176","author":"Gibson","year":"2019","journal-title":"Cell"},{"key":"2025090409162505000_22.2.141.15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00000441-199511000-00007","article-title":"Case report: subacute combined degeneration of the spinal cord from folate deficiency","volume":"310","author":"Ravakhah","year":"1995","journal-title":"Am J Med Sci"},{"key":"2025090409162505000_22.2.141.16","doi-asserted-by":"publisher","DOI":"10.1080\/08880010290057336"},{"key":"2025090409162505000_22.2.141.17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.wneu.2019.05.123","article-title":"Spinal cord toxicity from intrathecal chemotherapy: a case with clinicopathologic correlation","volume":"128","author":"Dornbos","year":"2019","journal-title":"World Neurosurg"},{"key":"2025090409162505000_22.2.141.18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00005072-197805000-00006","article-title":"An ultrastructural study of subacute combined degeneration of the spinal cord in vitamin B12-deficient rhesus monkeys","volume":"37","author":"Agamanolis","year":"1978","journal-title":"J Neuropathol Exp Neurol"},{"key":"2025090409162505000_22.2.141.19","doi-asserted-by":"crossref","first-page":"117955571880907","DOI":"10.1177\/1179555718809071","article-title":"Intrathecal methotrexate-induced necrotizing myelopathy: a case report and review of histologic features","volume":"11","author":"Tariq","year":"2018","journal-title":"Clin Med Insights Pathol"},{"key":"2025090409162505000_22.2.141.20","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.3892\/ol.2016.4519","article-title":"Transverse myelopathy occurring with intrathecal administration of methotrexate and cytarabine chemotherapy: a case report","volume":"11","author":"Pan","year":"2016","journal-title":"Oncol Lett"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/practneurol-2021-003154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T16:16:33Z","timestamp":1757002593000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/practneurol-2021-003154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,17]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1136\/practneurol-2021-003154"],"URL":"https:\/\/doi.org\/10.1136\/practneurol-2021-003154","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]}}}